# Mount Sinai Regional Drug Induced Liver Injury Network Site

> **NIH NIH U01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2021 · $146,238

## Abstract

Project Summary
A major goal of DILIN since its inception has been to identify genetic biomarkers that predict
predisposition to DILI and a poor prognosis. DILIN has identified both drug specific and general
biomarkers for predisposition to DILI. In course of her carrier, Dr. Nicoletti has been working
extensively on the predisposition to drug induced liver injury and joined the DILIN consortium. Dr.
Nicoletti has been actively involved in the ongoing DILIN genetic projects that profiled DILI cases
based on HLA alleles and common variants. She will continue to take an active role in carrying
out the ongoing GWAS and fine-mapping downstream analyses and on predicting DILI risk based
on calculation of Polygenic Risk Score. Given her extensive experience on HLA allele prediction
algorithms and subsequent association analyses, Dr. Nicoletti will continue leading studies within
DILIN HLA allele sequencing project in collaboration with other DILIN researchers. These efforts
led to several DILIN publications, but additional work remains to be done. In the past year, Dr.
Nicoletti focused her efforts in identifying and processing publicly available datasets to select
population controls that match the ethnicities of the large group of DILIN cases. With an enhanced
statistical power due to the genotyping of a large set of newly recruited DILIN samples, Dr Nicoletti
will lead the discovery of novel risk factors associated with DILI as phenotype or with Drug
specific-DILI and the replication of previously identified association signals. A particular effort will
be devolved to study the genetic susceptibility of Anabolic Steroid (AS)-DILI. Finally, since Dr.
Nicoletti discovered evidence that DILI might share genetic risk factors with other autoimmune
liver diseases like primary biliary cirrhosis, Dr Nicoletti will evaluate the genetic similarity between
DILI and other liver disease to better understand the pathophysiology of DILI and the role of the
genetic variants in the autoimmune traits.

## Key facts

- **NIH application ID:** 10476656
- **Project number:** 3U01DK100928-09S1
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Jawad Ahmad
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $146,238
- **Award type:** 3
- **Project period:** 2021-09-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10476656

## Citation

> US National Institutes of Health, RePORTER application 10476656, Mount Sinai Regional Drug Induced Liver Injury Network Site (3U01DK100928-09S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10476656. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*